Environment alters epigenome and causes cancer 当講座は千葉大学医学部で昭和42年に開設された生化学第二講座に端を発します。
平成25年に分子腫瘍学と改称し、癌エピゲノム研究を遂行しています。
論文リスト

  1. Atsushi Hata, Hidemi Suzuki, Takahiro Nakajima, Taiki Fujiwara, Yuki Shiina, Taisuke Kaiho, Takahide Toyoda, Terunaga Inage, Takamasa Ito, Yuichi Sakairi, Hajime Tamura, Hironobu Wada, Yoshito Yamada, Masako Chiyo, Keisuke Matsusaka, Masaki Fukuyo, Ken-ichi Shinohara, Sakae Itoga, Shinichiro Motohashi, Kazuyuki Matsushita, Atsushi Kaneda, Ichiro Yoshino. Differential gene analysis during the development of obliterative bronchiolitis in a murine orthotopic lung transplantation model: A comprehensive transcriptome-based analysis. PLoS One. 2020; 15: e0232884. epub 2020 May 8. doi: 10.1371/journal.pone.0232884.
  2. Sata Y, Nakajima T, Fukuyo M, Matsusaka K, Hata A, Morimoto J, Rahmutulla B, Ito Y, Suzuki H, Yoshino I, Kaneda A. High expression of CXCL14 is a biomarker of lung adenocarcinoma with micropapillary pattern. Cancer Sci, epub 13 May 2020. doi.org/10.1111/cas.14456.
  3. Yamamoto Y, Matsusaka K, Fukuyo M, Rahmutulla B, Matsue H, Kaneda A. Higher methylation subtype of malignant melanoma and its correlation with thicker progression and worse prognosis. Cancer Med, epub 14 May 2020. doi: 10.1002/cam4.3127
  4. Asakawa Y, Okabe A, Fukuyo M, Li W, Ikeda E, Mano Y, Funata S, Namba H, Fujii T, Kita K, Matsusaka K, Kaneda A. Epstein-Barr virus positive gastric cancer involves enhancer activation through ATF3. Cancer Sci, 111:1818-1828, 2020. Epub 2020 March 02. doi.org/10.1111/cas.14370
  5. Ailiken G, Kitamura K, Hoshino T, Satoh M, Tanaka N, Minamoto T, Rahmutulla B, Kobayashi S, Kano M, Tanaka T, Kaneda A, Nomura F, Matsubara H, Matsushita K. Posttranscriptional regulation of BRG1 by FIRΔexon2 in gastric cancer. Oncogenesis, 9: 26, 2020. doi: 10.1038/s41389-020-0205-4.
  6. Nakagawa T, Matsusaka K, Misawa K, Ota S, Fukuyo M, Rahmutulla B, Kunii N, Sakurai D, Hanazawa T, Matsubara H, Okamoto Y, Kaneda A. Stratification of HPV-associated and HPV-negative oropharyngeal squamous cell carcinomas based on DNA methylation epigenotypes. Int J Cancer, 146: 2460-2474, 2020. doi: 10.1002/ijc.32890.
  7. Kurokawa T, Nakagawa T, Matsusaka K, Fukuyo M, Mima M, Misawa K, Rahmutulla B, Ikeda J, Hanazawa T, Okamoto Y, Kaneda A. Establishment of epigenetic markers to predict irradiation efficacy against oropharyngeal cancer. Cancer Sci, 111:1407-16, 2020. doi.org/10.1111/cas.14338.
  8. Maimaiti M, Sakamoto S, Yamada Y, Sugiura M, Rii J, Takeuchi N, Imamura Y, Furihata T, Ando K, Higuchi K, Xu M, Sazuka T, Nakamura K, Kaneda A, Kanai Y, Kyprianou N, Ikehara Y, Anzai N, Ichikawa T. Expression of L-type amino acid transporter 1 as a molecular target for prognostic and therapeutic indicators in bladder carcinoma. Sci Rep, 10:1292, 2020. doi: 10.1038/s41598-020-58136-x.
  9. Fukayama M, Abe H, Kunita A, Shinozaki-Ushiku A, Matsusaka K, Ushiku T, Kaneda A. Thirty years of Epstein-Barr virus-associated gastric carcinoma. Virchows Archiv, 476:353-365, 2020. epub 2019 Dec 13. doi: 10.1007/s00428-019-02724-4
  10. Hokari S, Tamura Y, Kaneda A, Katsura A, Morikawa M, Murai F, Ehata S, Tsutsumi S, Ishikawa Y, Aburatani H, Kikuchi T, Miyazono K, Koinuma D. Comparative analysis of TTF-1-binding DNA regions in small cell lung cancer and nonsmall cell lung cancer. Mol Oncol, 14:277-293, 2020. epub 2019 Nov 29. doi: 10.1002/1878-0261.12608.
  11. Ooi WF, Nargund AM, Lim KJ, Zhang S, Xing M, Mandoli A, Lim JQ, Ho SWT, Guo Y, Yao X, Lin JS, Nandi T, Xu C, Ong X, Lee M, Tan ALK, Lam YN, Teo JX, Kaneda A, White KP, Lim WK, Rozen SG, Teh BT, Li S, Skanderup AJ, Tan P. Integrated Paired-end Enhancer Profiling and Whole-Genome Sequencing Reveals Recurrent CCNE1 and IGF2 Enhancer Hijacking in Primary Gastric Adenocarcinoma. Gut, 69:1039-1052, 2020. epub 2019 Sep 21. doi: 10.1136/gutjnl-2018-317612
  12. Eguchi A, Nishizawa-Jotaki S, Tanabe H, Rahmutulla B, Watanabe M, Miyaso H, Todaka E, Sakurai K, Kaneda A, Mori C. An Altered DNA Methylation Status in the Human Umbilical Cord Is Correlated with Maternal Exposure to Polychlorinated Biphenyls. Int J Environ Res Public Health, 16:2786, 2019. doi:10.3390/ijerph16152786
  13. Hata A, Nakajima T, Matsusaka K, Fukuyo M, Morimoto J, Yamamoto T, Sakairi Y, Rahmutulla B, Ota S, Wada H, Suzuki H, Matsubara H, Yoshino I, Kaneda A. A low DNA methylation epigenotype in lung squamous cell carcinoma and its association with idiopathic pulmonary fibrosis and poorer prognosis. Int J Cancer, 146:388-399, 2020. doi: 10.1002/ijc.32532..
  14. Qin R, Takayanagi S, Kondo Y, Li J, Shiga N, Nakajima M, Shinohara K, Yoda N, Suzuki T, Kaneda A, Nemoto T. Synthesis of LSD1 Inhibitor-Pyrrole-Imidazole Polyamide Conjugates for Region-Specific Alterations of Histone Modification. Heterocycles, 99: 891-905, 2019. DOI: 10.3987/COM-18-S(F)57
  15. Takane K, Fukuyo M, Matsusaka K, Ota S, Rahmutulla B, Matsushita K, Miyauchi H, Nakatani Y, Matsubara H, Kaneda A. The frequency of promoter DNA hypermethylation is decreased in colorectal neoplasms of familial adenomatous polyposis. Oncotarget, 9:32653-32666, 2018. doi: 10.18632/oncotarget.25987.
  16. Kawajiri-Manako C, Mimura N, Fukuyo M, Namba H, Rahmutulla B, Nagao Y, Togasaki E, Shimizu R, Oshima-Hasegawa N, Tsukamoto S, Mitsukawa S, Takeda Y, Ohwada C, Takeuchi M, Iseki T, Misawa S, Yokote K, Tsuiji M, Kuwabara S, Sakaida E, Kaneda A, Nakaseko C. Clonal immunoglobulin λ light-chain gene rearrangements detected by next generation sequencing in POEMS syndrome. Am J Hematol, 93:1161-1168, 2018. doi: 10.1002/ajh.25213.
  17. Fukayama M, Kunita A, Kaneda A. Gastritis-Infection-Cancer Sequence of Epstein-Barr Virus-Associated Gastric Cancer. Adv Exp Med Biol 1045:437-457, 2018. doi: 10.1007/978-981-10-7230-7_20.
  18. Alagarswamy K, Shinohara K, Takayanagi S, Fukuyo M, Okabe A, Rahmutulla B, Yoda N, Qin R, Shiga N, Sugiura M, Sato H, Kita K, Suzuki T, Nemoto T, Kaneda A. Region-specific alteration of histone modification by LSD1 inhibitor conjugated with pyrrole-imidazole polyamide. Oncotarget, 9:29316-35, 2018. doi: 10.18632/oncotarget.25451.
  19. Tamura A, Ogasawara T, Fujii Y, Kaneko H, Nakayama A, Higuchi S, Hashimoto N, Miyabayashi Y, Fujimoto M, Komai E, Kono T, Sakuma I, Nagano H, Suzuki S, Koide H, Yokote K, Iseki K, Oguma R, Matsue H, Nojima H, Sugiura K, Yoshitomi H, Ohtsuka M, Rahmutulla B, Kaneda A, Inoshita N, Ogawa S, Tanaka T. Glucagonoma with necrolytic migratory erythema: metabolic profile and detection of biallelic inactivation of DAXX gene. J Clin Endoclinol Metab, 103:2417-23, 2018. doi: 10.1210/jc.2017-02646.
  20. Kusano-Arai O, Iwanari H, Kudo S, Akiba H, Matsusaka K, Kaneda A, Fukayama M, Tsumoto K, Hamakubo T. Synergistic cytotoxic effect on gastric cancer cells of an immunotoxin cocktail in which antibodies recognize different epitopes on CDH17. Monoclon Antib Immunodiagn Immunother, 37:1-11, 2018. DOI: 10.1089/mab.2017.0043
  21. Okabe A, Kaneda A. Epigenetic aberration at enhancer regions in gastric cancer. J Cancer Treat Diagn, 2: 31-35, 2018.
  22. Nakagawa T, Matsusaka K, Misawa K, Ota S, Takane K, Fukuyo M, Rahmutulla B, Shinohara K, Kunii N, Sakurai D, Hanazawa T, Matsubara H, Nakatani Y, Okamoto Y, Kaneda A. Frequent promoter hypermethylation associated with human papillomavirus infection in pharyngeal cancer. Cancer Lett, 407: 21-31, 2017. doi: 10.1016/j.canlet.2017.08.008.
  23. Okabe A, Funata S, Matsusaka K, Namba H, Fukuyo M, Rahmutulla B, Oshima M, Iwama A, Fukayama M, Kaneda A. Regulation of tumour related genes by dynamic epigenetic alteration at enhancer regions in gastric epithelial cells infected by Epstein-Barr virus. Sci Rep, 7: 7924, 2017. doi: 10.1038/s41598-017-08370-7
  24. Funata S, Matsusaka K, Yamanaka R, Yamamoto S, Okabe A, Fukuyo M, Aburatani H, Fukayama M, Kaneda A. Histone modification alteration coordinated with acquisition of promoter DNA methylation during Epstein-Barr virus infection. Oncotarget, 8:55265-55279, 2017. doi: 10.18632/oncotarget.19423.
  25. Matsusaka K*, Funata S*, Fukuyo M, Seto Y, Aburatani H, Fukayama M, Kaneda A. Epstein-Barr virus infection induces genome-wide de novo DNA methylation in non-neoplastic gastric epithelial cells. J Pathol, 242:391-399, 2017. doi: 10.1002/path.4909. (*equal first authors)
  26. Shiga N, Takayanagi S, Muramoto R, Murakami T, Qin R, Suzuki Y, Shinohara K, Kaneda A, Nemoto T. Synthesis of pyrrole-imidazole polyamide oligomers based on a copper-catalyzed cross-coupling strategy. Bioorg Med Chem Lett 27:2197-2200, 2017. doi: 10.1016/j.bmcl.2017.03.052.
  27. Takane K. Akagi K. Fukuyo M. Yagi K. Takayama T. Kaneda A. DNA methylation epigenotype and clinical features of NRAS-mutation(+) colorectal cancer. Cancer Med, 6:1023-1035, 2017. doi: 10.1002/cam4.1061
  28. Hasegawa N, Oshima M, Sashida G, Matsui H, Koide S, Saraya A, Wang C, Muto T, Takane K, Kaneda A, Shimoda K, Nakaseko C, Yokote K, Iwama A. Impact of combinatorial dysfunctions of Tet2 and Ezh2 on the epigenome in the pathogenesis of myelodysplastic syndrome. Leukemia, 31:861-871, 2017. doi: 10.1038/leu.2016.268.
  29. Shinohara K, Yoda N, Takane K, Watanabe T, Fukuyo M, Fujiwara K, Kita K, Nagase H, Nemoto T, Kaneda A. Inhibition of DNA methylation at the MLH1 promoter region using pyrrole-imidazole polyamide. ACS Omega, 1:1164-72, 2016. doi: 10.1021/acsomega.6b00229.
  30. Namba-Fukuyo H, Funata S, Matsusaka K, Fukuyo M, Rahmutulla B, Mano Y, Fukayama M, Aburatani H, Kaneda A. TET2 functions as a resistance factor against DNA methylation acquisition during Epstein-Barr virus infection. Oncotarget, 7:81512-26, 2016. doi: 10.18632/oncotarget.13130.
  31. Matsusaka K, Ushiku T, Urabe M, Fukuyo M, Abe H, Ishikawa S, Seto Y, Aburatani H, Hamakubo T, Kaneda A, Fukayama M. Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer. Oncotarget, 7:64168-81, 2016. doi: 10.18632/oncotarget.11638.
  32. Takane K, Matsusaka K, Ota S, Fukuyo M, Yue Y, Nishimura M, Abe H, Sakai E, Matsushita K, Miyauchi H, Fukayama M, Aburatani H, Nakatani Y, Takayama T, Matsubara H, Akagi K, Kaneda A. Two subtypes of colorectal tumor with distinct molecular features in familial adenomatous polyposis. Oncotarget, 7:84003-16, 2016. doi: 10.18632/oncotarget.11510.
  33. Funata S, Fukayama M, Kaneda A. De novo methylation in cancer. In: Encyclopedia of Life Sciences (eLS). John Wiley & Sons, Ltd: Chichester. doi: 10.1002/9780470015902.a0026465
  34. Matsusaka K, Ishikawa S, Nakayama A, Ushiku T, Nishimoto A, Urabe M, Kaneko N, Kunita A, Kaneda A, Aburatani H, Fujishiro M, Seto Y, Fukayama M. Tumor Content Chart-Assisted HER2/CEP17 Digital PCR Analysis of Gastric Cancer Biopsy Specimens. PLoS One, 11:e0154430, 2016. doi: 10.1371/journal.pone.0154430.
  35. Kita K, Sugita K, Sato C, Sugaya S, Kaneda, A. Extracellular Release of Annexin A2 is Enhanced upon Oxidative Stress Response via the p38 MAPK Pathway after Low-Dose X-Ray Radiation. Radiat Res, 186: 79-91, 2016. doi: 10.1667/RR14277.1.
  36. Sakai E, Fukuyo M, Matsusaka K, Ohata K, Doi N, Takane K, Matsuhashi N, Fukushima J, Nakajima A, Kaneda A. TP53 mutation at early stage of colorectal cancer progression from two types of laterally spreading tumors. Cancer Sci, 107:820-7, 2016. doi: 10.1111/cas.12930.
  37. Saju P, Murata-Kamiya N, Hayashi T, Senda Y, Nagase L, Noda S, Matsusaka K, Funata S, Kunita A, Urabe M, Seto Y, Fukayama M, Kaneda A, Hatakeyama M. Host SHP1 phosphatase antagonizes Helicobacter pylori CagA and can be downregulated by EBV. Nat Microbiol, 1:16026, 2016. doi: 10.1038/nmicrobiol.2016.26.
  38. Fujimoto M, Mano Y, Anai M, Yamamoto S, Fukuyo M, Aburatani H, Kaneda A. Epigenetic alteration to activate Bmp2-Smad signaling in Raf-induced senescence. World J Biol Chem, 7:188-205, 2016. doi: 10.4331/wjbc.v7.i1.188.
  39. Suzuki Y, Tanaka Y, Nakano S, Dodo K, Yoda N, Shinohara K, Kita K, Kaneda A, Sodeoka M, Hamada Y, Nemoto T. Platinum-Catalyzed Friedel-Crafts-Type C-H Coupling-Allylic Amination Cascade to Synthesize 3,4-Fused Tricyclic Indoles. Chemistry, 22:4418-21, 2016. doi: 10.1002/chem.201600375
  40. Ishige T, Nishimura M, Satoh M, Fujimoto M, Fukuyo M,Semba T, Kado S, Tsuchida S, Sawai S, Matsushita K, Togawa A, Matsubara H, Kaneda A, Nomura F. Combined Secretomics and Transcriptomics Revealed Cancer-Derived GDF15 is Involved in Diffuse-Type Gastric Cancer Progression and Fibroblast Activation. Sci Rep, 6:21681, 2016. doi: 10.1038/srep21681
  41. Sakai E, Fukuyo M, Ohata K, Matsusaka K, Doi N, Mano Y, Takane K, Abe H, Yagi K, Matsuhashi N, Fukushima J, Fukayama M, Akagi K, Aburatani H, Nakajima A, Kaneda A. Genetic and epigenetic aberrations occurring in colorectal tumors associated with serrated pathway. Int J Cancer 138: 1634-44, 2016. doi: 10.1002/ijc.29903.
  42. Kaneda A, Nonaka A, Fujita T, Yamanaka R, Fujimoto M, Miyazono K, Aburatani H. Epigenomic regulation of Smad1 signaling during cellular senescence induced by Ras activation. Methods Mol Biol 1344:341-53, 2016. doi: 10.1007/978-1-4939-2966-5_22.
  43. Onodera A, Tumes DJ, Watanabe Y, Hirahara K, Kaneda A, Sugiyama F, Suzuki Y, Nakayama T. Spatial interplay between Polycomb and Trithorax complexes controls transcriptional activity in T lymphocytes. Mol Cell Biol 35:3841-53, 2015. doi: 10.1128/MCB.00677-15.
  44. Matsushita K, Kitamura K, Rahmutulla B, Tanaka N, Ishige T, Satoh M, Hoshino T, Miyagi S, Mori T, Itoga S, Shimada H, Tomonaga T, Kito M, Nakajima-Takagi Y, Kubo S, Nakaseko C, Hatano M, Miki T, Matsuo M, Fukuyo M, Kaneda A, Iwama A, Nomura F. Haploinsufficiency of the c-myc transcriptional repressor FIR, as a dominant negative-alternative splicing model, promoted p53-dependent T-cell acute lymphoblastic leukemia progression by activating Notch1. Oncotarget 6:5102-17, 2015. DOI: 10.18632/oncotarget.3244
  45. Kaneda A, Yagi K. Quantitative DNA methylation analysis for epigenotyping of colorectal cancer. Methods Mol Biol 1238:289-99, 2015. doi: 10.1007/978-1-4939-1804-1_15.
  46. Abe H, Kaneda A, Fukayama M. Epstein-Barr Virus-Associated Gastric Carcinoma: Use of Host Cell Machineries and Somatic Gene Mutations. Pathobiology. 82:212-23, 2015. doi: 10.1159/000434683.
  47. Sato T, Kita K, Sato C, Kaneda A. Hochu-ekki-to (Bu-zhong-yi-qi-tang), a herbal medicine, enhances cisplatin-induced apoptosis in HeLa cells. Mol Med Rep 2:6215-20, 2015.
  48. Takane K, Midorikawa Y, Yagi K, Sakai A, Aburatani H, Takayama T, Kaneda A. Aberrant promoter methylation of PPP1R3C and EFHD1 in plasma of colorectal cancer patients. Cancer Med 3:1235-45, 2014. doi: 10.1002/cam4.273.
  49. Kaneda A, Matsusaka K, Sakai E, Funata S. DNA methylation accumulation and its predetermination of future cancer phenotypes. J Biochem 20:978-87, 2014. doi: 10.1093/jb/mvu038.
  50. Matsusaka K, Funata S, Fukayama S, Kaneda A. DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J Gastroenterol 20:3916-26, 2014. doi: 10.3748/wjg.v20.i14.3916.
  51. Sakai E, Ohata K, Chiba H, Matsuhashi N, Doi N, Fukushima J, Endo H, Takahashi H, Tsuji S, Yagi K, Matsusaka K, Aburatani H, Nakajima A, Kaneda A. Methylation epigenotypes and genetic features in colorectal laterally spreading tumors. Int J Cancer 135:1586-95, 2014. doi: 10.1002/ijc.28814.
  52. Tanaka T, Arai M, Jiang X, Sugaya S, Kanda T, Fujii K, Kita K, Sugita K, Imazeki F, Miyashita T, Kaneda A, Yokosuka O. Downregulation of microRNA-431 by human interferon-β inhibits viability of medulloblastoma and glioblastoma cells via upregulation of SOCS6. Int J Oncol 44:1685-90, 2014. doi: 10.3892/ijo.2014.2317.
  53. Sakai E, Nakajima A, Kaneda A. Accumulation of aberrant DNA methylation during colorectal cancer development. World J Gastroenterol 20:978-87, 2014. doi: 10.3748/wjg.v20.i4.978.
  54. Tanaka T, Arai M, Minemura S, Oyamada A, Saito K, Jiang X, Tsuboi M, Sazuka S, Maruoka D, Matsumura T, Nakagawa T, Sugaya S, Kanda T, Katsuno T, Kita K, Kishimoto T, Imazeki F, Kaneda A, Yokosuka O. Expression level of sonic hedgehog correlates with the speed of gastric mucosa regeneration in artificial gastric ulcers. J Gastroenterol Hepatol 29:736-41, 2014. doi: 10.1111/jgh.12445
  55. Kikuchi Y, Tsuji E, Yagi K, Matsusaka K, Tsuji S, Kurebayashi J, Ogawa T, Aburatani H, Kaneda A. Aberrantly methylated genes in human papillary thyroid cancer and correlation of their methylation to BRAF/RAS mutation. Front Genet 4:271, 2013. doi: 10.3389/fgene.2013.00271.
  56. Sato T, Kaneda A, Tsuji S, Isagawa T, Yamamoto S, Fujita T, Yamanaka R, Tanaka Y, Nukiwa T, Marquez VE, Ishikawa Y, Ichinose M, Aburatani H. PRC2 overexpression and PRC2-target gene repression relating to poorer prognosis in small cell lung cancer. Sci Rep 3:1911, 2013. doi: 10.1038/srep01911.
  57. Kaneda A, Matsusaka K, Aburatani H, Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res 72:3445-3450, 2012. doi: 10.1158/0008-5472.CAN-11-3919.
  58. Wang L, Tsutsumi S, Kawaguchi T, Nagasaki K, Tatsuno K, Yamamoto S, Sang F, Sonoda K, Sugawara M, Saiura A, Hirono S, Yamaue H, Miki Y, Isomura M, Totoki Y, Nagae G, Isagawa T, Ueda H, Murayama-Hosokawa S, Shibata T, Sakamoto H, Kanai Y, Kaneda A, Noda T, Aburatani H. Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 22: 208-219, 2012. doi: 10.1101/gr.123109.111.
  59. Yagi K, Takahashi H, Akagi K, Matsusaka K, Seto Y, Aburatani H, Nakajima A, Kaneda A. Intermediate methylation epigenotype and its correlation to KRAS mutation in conventional colorectal adenoma. Am J Pathol 180: 616-625, 2012. doi: 10.1016/j.ajpath.2011.10.010.
  60. Matsusaka K, Kaneda A, Nagae G, Ushiku T, Kikuchi Y, Hino R, Uozaki H, Seto Y, Takada K, Aburatani H, Fukayama M. Classification of Epstein-Barr virus positive gastric cancers by definition of DNA methylation epigenotypes. Cancer Res 71:7187-7197, 2011. doi: 10.1158/0008-5472.CAN-11-1349.
  61. Kaneda A, Fujita T, Anai M, Yamamoto S, Nagae G, Morikawa M, Tsuji S, Oshima M, Miyazono K, Aburatani H. Activation of Bmp2-Smad1 signal and its regulation by coordinated alteration of H3K27 trimethylation in Ras-induced senescence. PLoS Genet 7:e1002359, 2011. doi: 10.1371/journal.pgen.1002359.
  62. Kaneda A, Yagi K. Two groups of DNA methylation markers to classify colorectal cancer into three epigenotypes. Cancer Sci 102:18-24, 2011. doi: 10.1111/j.1349-7006.2010.01712.x.
  63. Deng YB, Nagae G, Midorikawa Y, Yagi K, Tsutsumi S, Yamamoto S, Hasegawa K, Kokudo N, Aburatani H, Kaneda A. Identification of genes preferentially methylated in hepatitis C virus-related hepatocellular carcinoma. Cancer Sci 101:1501-10, 2010. doi: 10.1111/j.1349-7006.2010.01549.x.
  64. Yagi K, Akagi K, Hayashi H, Nagae G, Tsuji S, Isagawa T, Midorikawa Y, Nishimura Y, Sakamoto H, Seto Y, Aburatani H, Kaneda A. Three DNA methylation epigenotypes in human colorectal cancer. Clin Cancer Res 16:21-33, 2010. doi: 10.1158/1078-0432.CCR-09-2006.
  65. Kaneda A, Wang CJ, Cheong R, Timp W, Onyango P, Wen B, Iacobuzio-Donahue CA, Ohlsson R, Andraos R, Pearson MA, Sharov AA, Longo DL, Ko MS, Levchenko A, Feinberg AP. Enhanced sensitivity to IGF-II signaling links loss of imprinting of IGF2 to increased cell proliferation and tumor risk. Proc Natl Acad Sci USA 104:20926-31, 2007. DOI: 10.1073/pnas.0710359105
  66. Hayashi H, Nagae G, Tsutsumi S, Kaneshiro K, Kozaki T, Kaneda A, Sugisaki H, Aburatani H. High-resolution mapping of DNA methylation in human genome using oligonucleotide tiling array. Hum Genet 120: 701-11, 2007. DOI: 10.1007/s00439-006-0254-6
  67. Maekita T, Nakazawa K, Mihara M, Nakajima T, Yanaoka K, Iguchi M, Arii K, Kaneda A, Tsukamoto T, Tatematsu M, Tamura G, Saito D, Sugimura T, Ichinose M, Ushijima T. High levels of aberrant DNA methylation in Helicobacterpylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin Cancer Res 12: 989-95, 2006. DOI: 10.1158/1078-0432.CCR-05-2096
  68. Kaneda A, Feinberg AP. Loss of imprinting of IGF2: a common epigenetic modifier of intestinal tumor risk. Cancer Res 65: 11236-40, 2005. DOI: 10.1158/0008-5472.CAN-05-2959
  69. Chi XZ, Yang JO, Lee KY, Ito K, Sakakura C, Li QL, Kim HR, Cha EJ, Lee YH, Kaneda A, Ushijima T, Kim WJ, Ito Y, Bae SC. RUNX3 suppresses gastric epithelial cell growth by inducing p21(WAF1/Cip1) expression in cooperation with transforming growth factor β-activated SMAD. Mol Cell Biol 25: 8097-107, 2005. DOI: 10.1128/MCB.25.18.8097-8107.2005
  70. Sakatani T*, Kaneda A*, Iacobuzio-Donahue CA*, Carter MG, Witzel SD, Okano H, Ko MS, Ohlsson R, Longo DL, Feinberg AP. Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307: 1976-8, 2005. DOI: 10.1126/science.1108080 (*equal first authors)
  71. Furuta J, Kaneda A, Umebayashi Y, Otsuka F, Sugimura T, and Ushijima T. Silencing of the thrombomodulin gene in human malignant melanoma. Melanoma Res 15:15-20, 2005.
  72. Abe M, Ohira M, Kaneda A, Yagi Y, Yamamoto S, Kitano Y, Takato T, Nakagawara A, Ushijima T. CpG island methylator phenotype is a strong determinant of poor prognosis in neuroblastomas. Cancer Res 65: 828-34, 2005.
  73. Ushijima T, Watanabe N, Shimizu K, Miyamoto K, Sugimura T, Kaneda, A. Decreased fidelity in replicating CpG methylation patterns in cancer cells. Cancer Res 65: 11-17, 2005.
  74. Okochi-Takada E, Ichimura S, Kaneda A, Sugimura T, Ushijima, T. Establishment of a detection system for demethylating agents using an endogenous promoter CpG island. Mutat Res 568: 187-94, 2004.
  75. Kaneda A, Wakazono K, Tsukamoto T, Watanabe N, Yagi Y, Tatematsu M, Kaminishi M, Sugimura T, Ushijima, T. Lysyl Oxidase is a tumor-suppressor gene inactivated by methylation and loss of heterozygosity in human gastric cancers. Cancer Res 64: 6410-15, 2004.
  76. Kaneda A, Kaminishi M, Sugimura T, Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett 212: 203-10, 2004.
  77. Kaneda A, Tsukamoto T, Takamura-Enya T, Watanabe N, Kaminishi M, Sugimura T, Tatematsu M, Ushijima T. Frequent hypomethylation in multiple promoter CpG islands is associated with global hypomethylation, but not with frequent promoter hypermethylation. Cancer Sci 95: 58-64, 2004.
  78. Ushijima T, Watanabe N, Okochi E, Kaneda A, Sugimura T, Miyamoto K. Fidelity of the methylation pattern and its variation in the genome. Genome Res 13: 868-74, 2003.
  79. Kaneda A, Takai D, Kaminishi M, Okochi E, Ushijima T. Methylation-sensitive-representational difference analysis and its application to cancer research. Ann N Y Acad Sci 983: 131-41, 2003.
  80. Kaneda A, Kaminishi M, Yanagihara K, Sugimura T, Ushijima, T. Identification of silencing of nine genes in human gastric cancers. Cancer Res 62: 6645-50, 2002.
  81. Abe M, Okochi E, Kuramoto T, Kaneda A, Takato T, Sugimura T, Ushijima T. Cloning of the 5' Upstream Region of the Rat p16 Gene and Its Role in Silencing. Jpn J Cancer Res 93: 1100-6, 2002.
  82. Kaneda A, Kaminishi M, Nakanishi Y, Sugimura T, Ushijima T. Reduced expression of the insulin-induced protein 1 and p41 Arp2/3 complex genes in human gastric cancers. Int J Cancer 100: 57-62, 2002.
  83. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ, Lee KY, Nomura S, Lee CW, Han SB, Kim HM, Kim WJ, Yamamoto H, Yamashita N, Yano T, Ikeda T, Itohara S, Inazawa J, Abe T, Hagiwara A, Yamagishi H, Ooe A, Kaneda A, Sugimura T, Ushijima T, Bae SC, Ito Y. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 109: 113-24, 2002.
  84. McKenzie AN, Li X, Largaespada DA, Sato A, Kaneda A, Zurawski SM, Doyle EL, Milatovich A, Francke U, Copeland NG, Jenkins NA, Zurawski G. Structural comparison and chromosomal localization of the human and mouse IL-13 genes. J Immunol 150: 5436-44, 1993.